loading page

The Diagnostic and Therapeutic Prospects of Exosomes in Ovarian Cancer
  • +1
  • qianrun Chen,
  • Jiayan Shi,
  • Danhua Ruan,
  • ce Bian
qianrun Chen
Sichuan University West China Second University Hospital

Corresponding Author:chenqianrun@stu.scu.edu.cn

Author Profile
Jiayan Shi
Author Profile
Danhua Ruan
Sichuan University
Author Profile
ce Bian
Sichuan University West China Second University Hospital
Author Profile

Abstract

Exosomes are nano-sized vesicles derived from the endosomal system and involved in multitudinous biological and pathological processes. Emerging evidence has demonstrated that exosomes are closely related to the tumorigenesis and progression of ovarian cancer. Ovarian cancer-related exosomes have cell-specific constituents that could be leveraged for diagnosis. Additionally, exosomes are promising to treat ovarian cancer through functioning as delivery systems or participating in immunotherapy or serving as direct targets. In this review, we discussed the association of exosomes in ovarian cancer progression and look forward to the clinical significance of exosomes relevant to diagnosis and treatment.
09 Apr 2022Submitted to BJOG: An International Journal of Obstetrics and Gynaecology
17 Apr 2022Submission Checks Completed
17 Apr 2022Assigned to Editor
03 May 2022Reviewer(s) Assigned
23 May 2022Review(s) Completed, Editorial Evaluation Pending
08 Jun 2022Editorial Decision: Revise Major
12 Jul 20221st Revision Received
25 Jul 2022Review(s) Completed, Editorial Evaluation Pending
25 Jul 2022Submission Checks Completed
25 Jul 2022Assigned to Editor
05 Aug 2022Editorial Decision: Revise Major
31 Aug 20222nd Revision Received
06 Sep 2022Submission Checks Completed
06 Sep 2022Assigned to Editor
06 Sep 2022Review(s) Completed, Editorial Evaluation Pending
14 Dec 2022Editorial Decision: Revise Major
29 Dec 20223rd Revision Received
25 Jan 2023Submission Checks Completed
25 Jan 2023Assigned to Editor
25 Jan 2023Review(s) Completed, Editorial Evaluation Pending
24 Feb 2023Editorial Decision: Accept